Eliaz Therapeutics

About:

Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body

Website: http://eliaztherapeutics.com/

Top Investors: National Institutes of Health

Description:

ETI have developed a patented, unique medical device that removes galectin-3 from human blood. The device removes both bound and free galectin-3 from the circulation, offering a new treatment option that is less invasive and has fewer side-effects than other therapies. The single-use apheresis column selectively removes Galectin-3 from the body. It contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.